Abstract
When nanotechnology is used in medicine, it makes it easier to find and treat a wide range of diseases. One of the oral options for treating multiple sclerosis (MS) is dimethyl fumarate (DMF). DMF has been shown to be effective in lowering inflammatory diseases; nevertheless, it is characterized by several undesirable side effects that reduce pa¬tient compliance and add financial obstacles. The aim of this study was to use platelet membranes and platelet na¬noparticles to generate a drug delivery system that works like a cell, so as to treat MS. During the experiments, there is a chance that the DMF solution might harden at room temperature. Therefore, in order to produce solid lipid nano¬particles (SLNs), DMF was combined with biocompatible lipids. The creation of SLNs involved the use of hot emulsion and ultrasonication. These DMF-SLNs were characterized by means of scanning electron microscopy, and Fourier-transform infrared spectroscopy. The herein demonstrated enhanced qualities of the devised SLNs suggest that the formulation may be a potential, longer-acting formulation for the improved management of MS. SLNs could change the way many illnesses are treated in a big way, if they are used for the delivery of medicines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
